Smartnuclide Biopharma
Clinical trials sponsored by Smartnuclide Biopharma, explained in plain language.
-
New radioactive tracer aims to spot colorectal cancer more clearly
Diagnosis CompletedThis early-phase trial tested a radioactive tracer called 68Ga-NODAGA-SNA009 in 12 people with colorectal cancer. The tracer targets a protein (GPA33) found on cancer cells and is used with PET scans to see where the cancer is in the body. The main goals were to check safety and …
Phase: EARLY_PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New radioactive tracer could sharpen cancer scans
Diagnosis CompletedThis early-phase trial tested a new radioactive imaging agent called 68Ga-NOTA-SNA002 in 17 adults with solid tumors. The agent was injected into a vein, and researchers checked its safety, how it spreads in the body, and how well it shows up on PET scans. The goal was to see if …
Phase: PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Diagnosis
Last updated Jun 26, 2026 18:18 UTC